133 related articles for article (PubMed ID: 16823031)
1. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
[TBL] [Abstract][Full Text] [Related]
2. Defining a conformational ensemble that directs activation of PPARγ.
Chrisman IM; Nemetchek MD; de Vera IMS; Shang J; Heidari Z; Long Y; Reyes-Caballero H; Galindo-Murillo R; Cheatham TE; Blayo AL; Shin Y; Fuhrmann J; Griffin PR; Kamenecka TM; Kojetin DJ; Hughes TS
Nat Commun; 2018 May; 9(1):1794. PubMed ID: 29728618
[TBL] [Abstract][Full Text] [Related]
3. A structural basis for the activation of peroxisome proliferator-activated receptor gamma (PPARγ) by perfluorooctanoic acid (PFOA).
Pederick JL; Frkic RL; McDougal DP; Bruning JB
Chemosphere; 2024 Apr; 354():141723. PubMed ID: 38494006
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of a Coumarin-Based PPARγ Fluorescence Probe for Competitive Binding Assay.
Yoshikawa C; Ishida H; Ohashi N; Itoh T
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919837
[TBL] [Abstract][Full Text] [Related]
5. Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ.
Shang J; Kojetin DJ
bioRxiv; 2024 May; ():. PubMed ID: 38798544
[TBL] [Abstract][Full Text] [Related]
6. Engineering and optimization of an allosteric biosensor protein for peroxisome proliferator-activated receptor γ ligands.
Li J; Gierach I; Gillies AR; Warden CD; Wood DW
Biosens Bioelectron; 2011 Nov; 29(1):132-9. PubMed ID: 21893405
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Nelumbinis folium targeting PPARγ for weight management: A molecular docking and molecular dynamics simulations study.
Wong AR; Yang AWH; Gill H; Lenon GB; Hung A
Comput Biol Med; 2023 Nov; 166():107495. PubMed ID: 37742414
[TBL] [Abstract][Full Text] [Related]
8. Natural helix 9 mutants of PPARγ differently affect its transcriptional activity.
Broekema MF; Massink MPG; Donato C; de Ligt J; Schaarschmidt J; Borgman A; Schooneman MG; Melchers D; Gerding MN; Houtman R; Bonvin AMJJ; Majithia AR; Monajemi H; van Haaften GW; Soeters MR; Kalkhoven E
Mol Metab; 2019 Feb; 20():115-127. PubMed ID: 30595551
[TBL] [Abstract][Full Text] [Related]
9. Enhanced detection of ligand-PPARγ binding based on surface plasmon resonance through complexation with SRC1- or NCOR2-related polypeptide.
Wang Y; Luo M; Che L; Wu Q; Li J; Ma Y; Wang J; Liu C
Int J Biol Macromol; 2024 May; 268(Pt 1):131865. PubMed ID: 38670200
[TBL] [Abstract][Full Text] [Related]
10. Activation of PPARδ: from computer modelling to biological effects.
Kahremany S; Livne A; Gruzman A; Senderowitz H; Sasson S
Br J Pharmacol; 2015 Feb; 172(3):754-70. PubMed ID: 25255770
[TBL] [Abstract][Full Text] [Related]
11. A Combined Molecular Dynamics and Hydropathic INTeraction (HINT) Approach to Investigate Protein Flexibility: The PPARγ Case Study.
Agosta F; Cozzini P
Molecules; 2024 May; 29(10):. PubMed ID: 38792097
[TBL] [Abstract][Full Text] [Related]
12. Couple dynamics: PPARγ and its ligand partners.
Yu S; Xu HE
Structure; 2012 Jan; 20(1):2-4. PubMed ID: 22244751
[TBL] [Abstract][Full Text] [Related]
13. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.
Choi JH; Banks AS; Estall JL; Kajimura S; Boström P; Laznik D; Ruas JL; Chalmers MJ; Kamenecka TM; Blüher M; Griffin PR; Spiegelman BM
Nature; 2010 Jul; 466(7305):451-6. PubMed ID: 20651683
[TBL] [Abstract][Full Text] [Related]
14. A hydrogen-deuterium exchange mass spectrometry-based protocol for protein-small molecule interaction analysis.
Meng Q; Song YL; Zhou C; He H; Zhang N; Zhou H
Biophys Rep; 2023 Apr; 9(2):99-111. PubMed ID: 37753061
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen Deuterium Exchange and other Mass Spectrometry-based Approaches for Epitope Mapping.
Jethva PN; Gross ML
Front Anal Sci; 2023; 3():. PubMed ID: 37746528
[TBL] [Abstract][Full Text] [Related]
16. International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.
Burris TP; de Vera IMS; Cote I; Flaveny CA; Wanninayake US; Chatterjee A; Walker JK; Steinauer N; Zhang J; Coons LA; Korach KS; Cain DW; Hollenberg AN; Webb P; Forrest D; Jetten AM; Edwards DP; Grimm SL; Hartig S; Lange CA; Richer JK; Sartorius CA; Tetel M; Billon C; Elgendy B; Hegazy L; Griffett K; Peinetti N; Burnstein KL; Hughes TS; Sitaula S; Stayrook KR; Culver A; Murray MH; Finck BN; Cidlowski JA
Pharmacol Rev; 2023 Nov; 75(6):1233-1318. PubMed ID: 37586884
[TBL] [Abstract][Full Text] [Related]
17. The PPAR
Kaupang Å; Hansen TV
PPAR Res; 2020; 2020():9657380. PubMed ID: 32695150
[TBL] [Abstract][Full Text] [Related]
18. To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations.
Sullivan HJ; Wang X; Nogle S; Liao S; Wu C
PPAR Res; 2020; 2020():5314187. PubMed ID: 32308671
[TBL] [Abstract][Full Text] [Related]
19. Recurrent activating mutations of PPARγ associated with luminal bladder tumors.
Rochel N; Krucker C; Coutos-Thévenot L; Osz J; Zhang R; Guyon E; Zita W; Vanthong S; Hernandez OA; Bourguet M; Badawy KA; Dufour F; Peluso-Iltis C; Heckler-Beji S; Dejaegere A; Kamoun A; de Reyniès A; Neuzillet Y; Rebouissou S; Béraud C; Lang H; Massfelder T; Allory Y; Cianférani S; Stote RH; Radvanyi F; Bernard-Pierrot I
Nat Commun; 2019 Jan; 10(1):253. PubMed ID: 30651555
[TBL] [Abstract][Full Text] [Related]
20. PPARγ in Complex with an Antagonist and Inverse Agonist: a Tumble and Trap Mechanism of the Activation Helix.
Frkic RL; Marshall AC; Blayo AL; Pukala TL; Kamenecka TM; Griffin PR; Bruning JB
iScience; 2018 Feb; 5():69-79. PubMed ID: 30123887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
